129 related articles for article (PubMed ID: 15341955)
1. Synthesis and evaluation of novel oxazoline MMP inhibitors.
Cook GR; Manivannan E; Underdahl T; Lukacova V; Zhang Y; Balaz S
Bioorg Med Chem Lett; 2004 Oct; 14(19):4935-9. PubMed ID: 15341955
[TBL] [Abstract][Full Text] [Related]
2. Design, modelling, synthesis and biological evaluation of peptidomimetic phosphinates as inhibitors of matrix metalloproteinases MMP-2 and MMP-8.
Bianchini G; Aschi M; Cavicchio G; Crucianelli M; Preziuso S; Gallina C; Nastari A; Gavuzzo E; Mazza F
Bioorg Med Chem; 2005 Aug; 13(15):4740-9. PubMed ID: 15935680
[TBL] [Abstract][Full Text] [Related]
3. Quest for selectivity in inhibition of matrix metalloproteinases.
Brown S; Meroueh SO; Fridman R; Mobashery S
Curr Top Med Chem; 2004; 4(12):1227-38. PubMed ID: 15320723
[TBL] [Abstract][Full Text] [Related]
4. Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.
Scozzafava A; Supuran CT
Bioorg Med Chem Lett; 2002 Oct; 12(19):2667-72. PubMed ID: 12217351
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.
Yan YL; Miller MT; Cao Y; Cohen SM
Bioorg Med Chem Lett; 2009 Apr; 19(7):1970-6. PubMed ID: 19261472
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.
Moriyama H; Tsukida T; Inoue Y; Kondo H; Yoshino K; Nishimura S
Bioorg Med Chem Lett; 2003 Aug; 13(16):2741-4. PubMed ID: 12873505
[TBL] [Abstract][Full Text] [Related]
8. Zinc-binding groups modulate selective inhibition of MMPs.
Agrawal A; Romero-Perez D; Jacobsen JA; Villarreal FJ; Cohen SM
ChemMedChem; 2008 May; 3(5):812-20. PubMed ID: 18181119
[TBL] [Abstract][Full Text] [Related]
9. Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.
Reiter LA; Mitchell PG; Martinelli GJ; Lopresti-Morrow LL; Yocum SA; Eskra JD
Bioorg Med Chem Lett; 2003 Jul; 13(14):2331-6. PubMed ID: 12824028
[TBL] [Abstract][Full Text] [Related]
10. Role of sulfonamide group in matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Xu WF
Curr Med Chem; 2008; 15(4):368-73. PubMed ID: 18288991
[TBL] [Abstract][Full Text] [Related]
11. Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating arylsulfonylureido and 5-dibenzo-suberenyl/suberyl moieties.
Ilies M; Banciu MD; Scozzafava A; Ilies MA; Caproiu MT; Supuran CT
Bioorg Med Chem; 2003 May; 11(10):2227-39. PubMed ID: 12713832
[TBL] [Abstract][Full Text] [Related]
12. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme].
Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ
Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase inhibitors: specificity of binding and structure-activity relationships.
Gupta SP
Exp Suppl; 2012; 103():v-vi. PubMed ID: 22642187
[No Abstract] [Full Text] [Related]
14. A quantitative structure-activity relationship study on some novel series of hydroxamic acid analogs acting as matrix metalloproteinase inhibitors.
Kumaran S; Gupta SP
Med Chem; 2007 Mar; 3(2):167-73. PubMed ID: 17348854
[TBL] [Abstract][Full Text] [Related]
15. Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
Fray MJ; Burslem MF; Dickinson RP
Bioorg Med Chem Lett; 2001 Feb; 11(4):567-70. PubMed ID: 11229773
[TBL] [Abstract][Full Text] [Related]
16. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.
Skiles JW; Gonnella NC; Jeng AY
Curr Med Chem; 2001 Mar; 8(4):425-74. PubMed ID: 11172697
[TBL] [Abstract][Full Text] [Related]
17. The application of x-ray, NMR, and molecular modeling in the design of MMP inhibitors.
Rush TS; Powers R
Curr Top Med Chem; 2004; 4(12):1311-27. PubMed ID: 15320728
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloprotease inhibitors: design from structure.
Borkakoti N
Biochem Soc Trans; 2004 Feb; 32(Pt 1):17-20. PubMed ID: 14748704
[TBL] [Abstract][Full Text] [Related]
20. From model complexes to metalloprotein inhibition: a synergistic approach to structure-based drug discovery.
Puerta DT; Schames JR; Henchman RH; McCammon JA; Cohen SM
Angew Chem Int Ed Engl; 2003 Aug; 42(32):3772-4. PubMed ID: 12923840
[No Abstract] [Full Text] [Related]
[Next] [New Search]
